ABSTRACT
In a double-blind, parallel-group, multicenter comparative trial in 127 evaluable patients with chronic, localized atopic dermatitis or lichen simplex chronicus, healing was reported in a higher percentage of patients treated with halobetasol propionate ointment than in those in the clobetasol propionate treatment group (65.1% versus 54.7%). The success rates (described as "healed" and "marked improvement") were practically identical in the two treatment groups (93.7% versus 92.2%). Early onset of therapeutic effect, that is, within 3 days of the start of treatment, was similar in the two treatment groups (24% versus 28%). Both preparations were well tolerated. Adverse effects were reported in 5% and 2% of the patients treated with halobetasol propionate and clobetasol propionate ointments, respectively.
Subject(s)
Clobetasol/analogs & derivatives , Dermatitis, Atopic/drug therapy , Neurodermatitis/drug therapy , Vasoconstrictor Agents/therapeutic use , Adolescent , Adult , Aged , Aged, 80 and over , Chronic Disease , Clobetasol/administration & dosage , Clobetasol/therapeutic use , Double-Blind Method , Female , Germany , Humans , Male , Middle Aged , Ointments , Patient Satisfaction , Remission Induction , Vasoconstrictor Agents/administration & dosage , Wound HealingABSTRACT
A multicentre double-blind clinical trial comparing two nasal solutions of naaga (magnesium salt of N-acetyl aspartyl glutamic acid-rhinaaxia) and of disodium cromoglycate (LOMUPREN) has been performed on 91 patients suffering from an acute symptomatic seasonal rhinitis treated for 28 days. Nasal, ocular and bronchial symptoms as well as side effects were recorded by the physician at the control visits and daily by the patient in a diary. Haematological parameters, blood chemistry and serum levels of non specific IgE were also measured. The results show: On the whole, there was no significant difference between groups, neither for the global appreciation of the therapeutic effect as assessed by the physician and the patient, nor for the daily evolution of the symptoms based on the patient's daily notebook. Both treatments were very well tolerated. In a selected population with IgE greater than 150 U/ml, there was a significantly better activity of naaga (p less than 0.05) on the disappearance of the ocular symptoms. The nasal symptoms appeared to improve significantly better in the cromoglycate group (p less than 0.05).
